Literature DB >> 3508057

Gaucher disease (type III): intellectual profile.

A Erikson1, J Karlberg, A L Skogman, S Dreborg.   

Abstract

In 20 patients with Gaucher disease type III (Norrbottnian variant), long-term intellectual prognoses were analyzed on the basis of psychometric tests which were performed on an average of five tests per patient. Intellectual delay was not found to be characteristic of the early stages of the disease. Slow regression occurred through childhood and adolescence. Patients splenectomized at an early stage averaged lower IQ scores in the long-term than those in whom the spleen had been spared as long as possible. These data added to other evidence of increased neurologic and other organ impairment after splenectomy, support the view that the spleen should not be removed in other than emergent situations.

Entities:  

Mesh:

Year:  1987        PMID: 3508057     DOI: 10.1016/0887-8994(87)90033-6

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  6 in total

Review 1.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 2.  Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

Authors:  E H Davies; A Erikson; T Collin-Histed; E Mengel; A Tylki-Szymanska; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

Review 3.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

4.  Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease.

Authors:  Panagiota Tsitsi; Ioanna Markaki; Josefine Waldthaler; Maciej Machaczka; Per Svenningsson
Journal:  JIMD Rep       Date:  2021-11-21

5.  Variation in cognitive function over time in Gaucher disease type 3.

Authors:  Alta M Steward; Edythe Wiggs; Taylor Lindstrom; Somto Ukwuani; Emory Ryan; Nahid Tayebi; Tamanna Roshan Lal; Grisel Lopez; Raphael Schiffmann; Ellen Sidransky
Journal:  Neurology       Date:  2019-11-12       Impact factor: 11.800

6.  Health-related quality of life in children and adolescents living with Gaucher disease and their parents.

Authors:  Eduardo Remor; Antonio Baldellou
Journal:  Health Psychol Behav Med       Date:  2018-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.